You have 9 free searches left this month | to do more

bosutinib

Bosutinib is a drug used to treat Chronic Myeloid Leukemia, Healthy, and Breast Cancer. Bosutinib is being actively studied in 16 studies and prior, has been studied in 20.

Top SponsorsTop SitesTop Investigators
PfizerPfizer Investigational SiteHaruhisa Inoue
Wyeth is now a wholly owned subsidiary of PfizerM D Anderson Cancer CenterNagla Abdel Karim
M.D. Anderson Cancer CenterRoswell Park Cancer InstituteSheldon Jordan
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Recruiting
  • Healthy Participants
  • Bosutinib capsule
  • Bosutinib
  • Brussels, Bruxelles-capitale, Région DE, Belgium
    Brussels Clinical Research Unit
2022-02-08
Feb 8, 2022
N
Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +7 more
  • Augusta, Georgia
    Augusta University Georgia Cancer Center
2021-07-31
Jul 31, 2021
P
Recruiting
  • Chronic Myelogenous Leukemia
  • Bosutinib
  • Shibuya-ku, Japan
    (unnamed)
2020-12-29
Dec 29, 2020
M
Completed
  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • +6 more
  • Bosutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-25
Mar 25, 2022
K
Recruiting
  • Amyotrophic Lateral Sclerosis
  • Bosutinib
  • Kyoto, Japan
  • +3 more
2021-02-03
Feb 3, 2021
S
Recruiting
  • Chronic Myeloid Leukemia
  • Aalborg, Denmark
  • +17 more
2022-04-04
Apr 4, 2022
M
Terminated
  • Accelerated Phase Chronic Myelogenous Leukemia (CML)
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2020-11-17
Nov 17, 2020
G
Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center
2022-01-17
Jan 17, 2022
P
Completed
  • Leukemia, Chronic Myelogenous
  • Bosutinib
  • Toyoake-City, Aichi, Japan
  • +20 more
2022-03-04
Mar 4, 2022
M
Terminated
  • Blasts Under 15 Percent of Bone Marrow Nucleated Cells
  • +4 more
  • Bosutinib
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
2020-04-22
Apr 22, 2020
P
Completed
  • Chronic Myeloblastic Leukaemia
  • Bosutinib
  • Gran Canaria, Spain
  • +12 more
2020-04-28
Apr 28, 2020
N
Not yet recruiting
  • Chronic Myelogenous Leukemia
  • Asciminib single agent
  • +6 more
  • (no location specified)
2021-11-25
Nov 25, 2021
N
Enrolling by invitation
  • Mild Cognitive Impairment
  • Dementia
  • bosutinib
  • Santa Monica, California
    Neurological Associates of West LA
2021-02-25
Feb 25, 2021
U
Active, not recruiting
  • CML, Chronic Phase
  • +4 more
  • Bosutinib
  • +3 more
  • Chapel Hill, North Carolina
    UNC Hospital
2021-08-27
Aug 27, 2021
N
Active, not recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Moscow, Russian Federation
    National Research Center for Hematology
2020-10-01
Oct 1, 2020
U
Completed
  • Leukemia
  • +3 more
  • Bosutinib
  • +2 more
  • Monza, Italy/MB, Italy
  • +1 more
2020-11-03
Nov 3, 2020
C
Recruiting
  • Philadelphia Chromosome Positive CML
  • +3 more
  • Bosutinib
  • Birmingham, Alabama
  • +40 more
2022-02-28
Feb 28, 2022
P
Completed
  • Chronic Myeloid Leukaemia
  • Bosutinib
  • Liverpool, Merseyside, United Kingdom
  • +2 more
2019-05-01
May 1, 2019
G
Active, not recruiting
  • Chronic Myeloid Leukemia
  • Bosutinib
  • Alessandria, Italy
  • +44 more
2022-01-04
Jan 4, 2022
C
Recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • Edmonton, Alberta, Canada
  • +9 more
2022-03-14
Mar 14, 2022
N
Active, not recruiting
  • Chronic Myelogenous Leukemia
  • Chicago, Illinois
  • +87 more
2022-03-21
Mar 21, 2022